Liquidia Corporation is a biopharmaceutical company focused on therapies for rare cardiopulmonary diseases, primarily in the United States. The company develops, manufactures, and commercializes treatments aimed at addressing unmet patient needs in pulmonary hypertension. Its key product, Yutrepia, is an inhaled dry powder formulation of treprostinil used for patients with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, delivered via a user-friendly inhalation device to support chronic outpatient management. Liquidia also commercializes and develops treprostinil-based therapies in other formulations, including continuous infusion and investigational liposomal and inhaled sustained-release products, often under licensing collaborations. By concentrating on specialized cardiopulmonary indications and leveraging drug-delivery innovation, Liquidia plays a targeted role within the U.S. pharmaceuticals and biotech sector, serving pulmonologists, specialty clinics, and hospital systems involved in advanced respiratory and vascular care. Founded in 2004 and headquartered in Morrisville, North Carolina, the company operates within the broader healthcare ecosystem as a niche provider of advanced pulmonary hypertension treatments.